Entropy strengthens IP with South African patent granted

Résumé détaillé

The patent titled Psilocin Crystalline Forms follows the grant of a corresponding Australian patent earlier in 2026. ... Read More The post Entropy strengthens IP with South…

Entropy has strengthened its IP on grant of a South African patent. Pic: Getty Images.

Special Report: Entropy Neurodynamics has been granted a South African patent covering proprietary crystalline forms of psilocin, expanding its international intellectual property portfolio supporting development of lead psychedelic therapy TRP-8803.

The patent titled Psilocin Crystalline Forms follows the grant of a corresponding Australian patent earlier in 2026.

Entropy Neurodynamics (ASX:ENP) said the patent covered crystalline forms of psilocin, the active metabolite of psilocybin, alongside associated pharmaceutical compositions and preparation methods.

It said the crystalline forms offered improved stability, solubility and consistency compared with conventional psilocin formulations, addressing key considerations in pharmaceutical development and manufacturing.

The patent complements ENPs existing IP portfolio and underpins its proprietary precision-controlled intravenous (IV) psilocin treatment platform TRP-8803.

While the platform focuses on controlled psilocin administration, ENP said the new patent protected specific crystalline forms and associated formulations, broadening its IP position across complementary aspects of psilocin-based drug development.

The South African patent has a term of 20 years from September 12, 2023, subject to applicable renewal fees, providing protection to 2043.

ENP’s broader IP portfolio now includes granted Australian patents covering its proprietary precision controlled IV dosing methodology and psilocin crystalline forms, alongside South African patents protecting fibromyalgia treatment methods and crystalline psilocin formulations.

Début de l'article, extrait de Stockhead. Pour lire la suite, ouvrez l'article chez le média.